Acrivon Therapeutics
ACRV
42 hedge funds and large institutions have $74.5M invested in Acrivon Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
0.6% more ownership
Funds ownership: 68.39% → 68.99% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 43 → 42 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
48% less capital invested
Capital invested by funds: $144M → $74.5M (-$69.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$288K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$243K |
| 3 |
BlackRock
New York
|
+$196K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$169K |
| 5 |
Morgan Stanley
New York
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$78.2K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$61K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$15K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.21K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$2.57K |
ACRV Hedge Fund Activity: Q4 2023 in Review
42 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2023, worth a combined $74.5M — down 48% from $144M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ACRV and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 16 added.
The largest buyer was DAFNA Capital Management, adding an estimated $288K. The largest seller was D.E. Shaw & Co, cutting an estimated $78.2K.
- 42 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2023, down from 43 in Q3 2023.
- Funds reported $74.5M of Acrivon Therapeutics stock for Q4 2023, down 48% quarter-over-quarter.
- 3 funds opened new Acrivon Therapeutics positions in Q4 2023 and 4 closed out, a net change of -1 holder.
- The largest Acrivon Therapeutics buyer in Q4 2023 was DAFNA Capital Management, an estimated $288K added.
- The largest Acrivon Therapeutics seller in Q4 2023 was D.E. Shaw & Co, an estimated $78.2K sold.
Based on aggregated 13F filings for Q4 2023.